Aclaris Therapeutics (ACRS) Operating Margin (2017 - 2026)

Aclaris Therapeutics' Operating Margin history runs 10 years deep, the most recent figure standing at 1111.82% for Q1 2026.

• In Q1 2026, Operating Margin rose 13106.0% year-over-year to 1111.82%; the TTM figure through Mar 2026 stood at 961.91% (down 16832.0% YoY), while the FY2025 annual figure was 975.91%, down 21773.0% from the prior year.
• Operating Margin was 1111.82% for Q1 2026 at Aclaris Therapeutics, up from 1755.52% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 23.03% in Q4 2023 to a low of 1755.52% in Q4 2025.
• Historically, Operating Margin has averaged 861.89% across 5 years, with a median of 1035.9% in 2025.
• Biggest YoY gain for Operating Margin was 123753 bps in 2024; the steepest drop was 105910 bps in 2024.
• A 5-year view of Operating Margin shows it stood at 375.07% in 2022, then surged by 94 bps to 23.03% in 2023, then sank by 4598 bps to 1082.13% in 2024, then slumped by 62 bps to 1755.52% in 2025, then surged by 37 bps to 1111.82% in 2026.
• The last three Operating Margin figures came in at 1111.82% (Q1 2026), 1755.52% (Q4 2025), and 519.82% (Q3 2025), per Business Quant data.